![Lonza Group AG Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/six/lonn.png?tr=w-200)
Lonza Group AG
SIX:LONN
![Lonza Group AG Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/six/lonn.png)
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
311.5
581
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/six/lonn.png)
Intrinsic Value
Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. [ Read More ]
The intrinsic value of one
LONN
stock under the Base Case scenario is
564.14
CHF.
Compared to the current market price of 581 CHF,
Lonza Group AG
is
Overvalued by 3%.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/six/lonn.png?tr=w-200)
Valuation Backtest
Lonza Group AG
Run backtest to discover the historical profit from buying and selling
LONN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Lonza's Steady Outlook Amid Q1 Softness and Future Growth Plans
Earnings Call Summary
Lonza reported softer performance in Q1 2024 due to batch timing and weaker demand in some divisions. However, they maintain confidence in their full-year outlook with a flat constant currency revenue growth and CORE EBITDA margins between 27% and 29%. Strong commercial demand in Biologics and significant future growth from the Roche agreement are expected to drive H2 improvements. Ongoing projects, including new facilities in Switzerland, indicate progress. The company also advanced its share buyback program and confirmed Wolfgang Wienand as the new CEO starting in summer 2024.
Balance Sheet Decomposition
Lonza Group AG
Current Assets | 4.9B |
Cash & Short-Term Investments | 1.7B |
Receivables | 1.2B |
Other Current Assets | 2.1B |
Non-Current Assets | 11.9B |
PP&E | 6.6B |
Intangibles | 4.7B |
Other Non-Current Assets | 589m |
Current Liabilities | 2.8B |
Accounts Payable | 468m |
Other Current Liabilities | 2.3B |
Non-Current Liabilities | 4.6B |
Long-Term Debt | 2.6B |
Other Non-Current Liabilities | 2B |
Earnings Waterfall
Lonza Group AG
Revenue
|
6.7B
CHF
|
Cost of Revenue
|
-4.3B
CHF
|
Gross Profit
|
2.4B
CHF
|
Operating Expenses
|
-1.1B
CHF
|
Operating Income
|
1.3B
CHF
|
Other Expenses
|
-677m
CHF
|
Net Income
|
654m
CHF
|
Free Cash Flow Analysis
Lonza Group AG
CHF | |
Free Cash Flow | CHF |
LONN Profitability Score
Profitability Due Diligence
Lonza Group AG's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/six/lonn.png)
Score
Lonza Group AG's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
LONN Solvency Score
Solvency Due Diligence
Lonza Group AG's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/six/lonn.png)
Score
Lonza Group AG's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LONN Price Targets Summary
Lonza Group AG
According to Wall Street analysts, the average 1-year price target for
LONN
is 593.4 CHF
with a low forecast of 328.25 CHF and a high forecast of 699.3 CHF.
Price Appreciation
LONN Price
Lonza Group AG
Average Annual Return | 14.46% |
Standard Deviation of Annual Returns | 42.18% |
Max Drawdown | -60% |
Market Capitalization | 41.8B CHF |
Shares Outstanding | 72 116 600 |
Percentage of Shares Shorted |
N/A
|
Company Profile
![Lonza Group AG Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/six/lonn.png?tr=w-200)
![Lonza Group AG Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/six/lonn.png?tr=w-200)
Country
Industry
Market Cap
Dividend Yield
Description
Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 16,218 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Contact
IPO
Employees
Officers
The intrinsic value of one
LONN
stock under the Base Case scenario is
564.14
CHF.
Compared to the current market price of 581 CHF,
Lonza Group AG
is
Overvalued by 3%.